Corporate Information

Developing innovative treatment methods and creating new value

Since its establishment in February 2011, Otsuka Medical Devices Co., Ltd. has focused on developing unique solutions that improve the health and well-being of patients whose medical needs and conditions cannot yet be fulfilled by existing treatment methods. To achieve our aspiration of becoming a pioneer in the medical device industry, we combine global R&D efforts with the technology and drug discovery know-how inherent within the Otsuka group’s heritage.
We will do what it takes to offer patients new innovative treatment choices and stand true to the Otsuka corporate philosophy:“Otsuka-people creating new products for better health worldwide”.

Otsuka Medical Devices Group Video

Company Name Otsuka Medical Devices Co., Ltd.
Established February 15th, 2011
Capital 7.55 billion yen
Head Office 2-9, Kanda-Tsukasamachi, Chiyoda-ku, Tokyo 101-0048, Japan
Tokyo Headquarters Shinagawa Grand Central Tower 13F 2-16-4, Konan, Minato-ku, Tokyo 108-0075, Japan [Location]
Employees 136 (As of December 31, 2023)
Business Description R&D, manufacture, and sales of medical devices and all related operations, as well as medical device operational management for companies within the Otsuka group
Shareholder Otsuka Holdings Co., Ltd. (100%)

Board of Directors

President and
Representative Director
Noriko Tojo
Deputy President
Kazumichi Kobayashi
Executive Director Yoshiro Matsuo
Executive Director Kuniaki Natsume
Outside Director Tomiko Tawaragi
Statutory Auditor Yasuhiro Gomi
Outside Audit &
Supervisory Board Member
Naoki Miyamori
Executive Vice President Shinji Iizuka
Senior Vice President Christian Bell

(As of March 8, 2024)


February 2011 Otsuka Medical Devices is newly established as holding company for Otsuka group’s medical device activities including JIMRO Co., Ltd. (apheresis business) and Otsuka Pharmaceutical’s interests in MicroPort Scientific Corporation
October 2011 Acquisition of KiSCO Co., Ltd., a Japanese company specializing in spine and fractures
May 2016 Otsuka Holdings announces collaboration with ReCor Medical, Inc. regarding an equity investment and commercialization of ReCor’s ultrasound renal denervation technology in Asia
February 2017 Acquisition of Biomedical Solutions Inc., a Japanese venture designing novel stent retriever in ischemic stroke, through JIMRO Co., Ltd.
November 2018 ReCor Medical, Inc. becomes fully-owned subsidiary of Otsuka Medical Devices
December 2018 Veryan Medical Limited becomes fully-owned subsidiary of Otsuka Medical Devices
February 2022 Transferred KiSCO’s spine and trauma businesses to Teijin Nakashima Medical Co., Ltd.